This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Safety Profile | DVT/PE Treatment | Pradaxa® (dabigatran etexilate) Skip to main content

*Patients in the RE‑COVER® and RE‑COVER II™ Trials had a mean exposure of 164 days during the oral‑only treatment period.
Patients with at least one major bleeding event.

  • References:
  • 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.